V 20

Drug Profile

V 20

Alternative Names: V20

Latest Information Update: 22 Aug 2002

Price : $50

At a glance

  • Originator GLYCODesign
  • Class Antiplatelets; Vascular disorder therapies
  • Mechanism of Action Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 22 Aug 2002 Discontinued - Preclinical for Thrombosis in Canada (unspecified route)
  • 22 Aug 2002 Discontinued - Preclinical for Thrombosis in USA (unspecified route)
  • 13 Sep 2000 A preclinical study has been added to the Thromboses pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top